Effect of HBIG combined with hepatitis B vaccine on blocking HBV transmission between mother and infant and its effect on immune cells

Gong,Junling; Liu,Xing

doi:10.3892/etm.2017.5474

Effect of HBIG combined with hepatitis B vaccine on blocking HBV transmission between mother and infant and its effect on immune cells

Authors:
- Junling Gong
- Xing Liu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China, Department of Infectious Disease, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China
Published online on: November 9, 2017 https://doi.org/10.3892/etm.2017.5474
Pages: 919-923
Copyright: © Gong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The effect of hepatitis B immune globulin (HBIG) combined with hepatitis B vaccine on blocking hepatitis B virus (HBV) transmission between mother and infant and its effect on immune cells were studied. Ninety newborn infants confirmed to be HBV surface antigen (HBsAg)-positive were divided equally into three groups. Group A newborns received the hepatitis B vaccine at 0, 1 and 6 months after birth (10 µg/time). Group B newborns received an intramuscular injection of 100 IU HBIG 2 h after birth before the same treatment as group A. Mothers of group C newborns received three gluteus maxinus injections of 200 IU HBIG. The newborns in group C got the same treatment as group B. The blocking effect of HBV transmission between mother and infant was evaluated, and cell immune function was assessed. There were significant differences in comparison of blocking success rates between group A and B, and between group A and C as well (p<0.05). At the end of 12 months follow-up, the CD4+ level and CD4+/CD8+ ratio in group C were higher thanthose in group A and B (p<0.05). In addition, the level of CD8+ T lymphocyte in group C was lower than those in group A and B (p<0.05). In comparison of levels of CD4+T lymphocyte at the end of 12 months follow-up and 24 h after birth, the differences were significant (p<0.05) in bothgroup B and C. The differences of IFN-γ levels betweengroups B/C and group A were significant (p<0.05). Forthose newborn infants born to mothers who were positivefor both HBsAg and HBeAg, HBIG intervention formothers during late pregnancy, together with combinedtreatment of HBIG and hepatitis B vaccine for infants, gavebetter blocking result of HBV transmission.

View Figures

View References

1	Alavian SM, Fallahian F and Lankarani KB: The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 16:403–406. 2007.PubMed/NCBI
2	Rehermann B and Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 5:215–229. 2005. View Article : Google Scholar : PubMed/NCBI
3	Feng YL, Wang SP, Wei JN, Shi XH, Zhang JB, Guo Q, Wu XB, Fan H and Wang XF: Comprehensive study on the risk factors of hepatitis B virus intrauterine infection. Zhonghua Liu Xing Bing Xue Za Zhi. 29:132–135. 2008.(In Chinese). PubMed/NCBI
4	Komatsu H, Inui A, Sogo T, Hiejima E, Tateno A, Klenerman P and Fujisawa T: Cellular immunity in children with successful immunoprophylactic treatment for mother-to-child transmission of hepatitis B virus. BMC Infect Dis. 10:1032010. View Article : Google Scholar : PubMed/NCBI
5	Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY and Chen CL: Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 2:1099–1102. 1983. View Article : Google Scholar : PubMed/NCBI
6	Liang YL and Fu SM: Immunity mechanism of vertical transmission blocking for HBV immunoglobulin injection to pregnant women. Chin J Immunol. 31:818–821. 2015.
7	Wang GL, Liu Y, Qiu P, Zhou SF, Xu LF, Wen P, Wen JB and Xiao XZ: Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis. Eur Rev Med Pharmacol Sci. 20:866–872. 2016.PubMed/NCBI
8	Han GR, Jiang HX, Yue X, Ding Y, Wang CM, Wang GJ and Yang YF: Efficacy and safety of telbivudine treatment: An open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection. J Viral Hepat. 22:754–762. 2015. View Article : Google Scholar : PubMed/NCBI
9	Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 11:97–107. 2004. View Article : Google Scholar : PubMed/NCBI
10	Luna EJ, Moraes JC, Silveira L and Salinas HS: Efficacy and safety of the Brazilian vaccine against hepatitis B in newborns. Rev Saude Publica. 43:1014–1020. 2009.(In Portuguese). View Article : Google Scholar : PubMed/NCBI
11	Ko SC, Schillie SF, Walker T, Veselsky SL, Nelson NP, Lazaroff J, Crowley S, Dusek C, Loggins K, Onye K, et al: Hepatitis B vaccine response among infants born to hepatitis B surface antigen-positive women. Vaccine. 32:2127–2133. 2014. View Article : Google Scholar : PubMed/NCBI
12	Féray C, Gigou M, Samuel D, Ducot B, Maisonneuve P, Reynès M, Bismuth A and Bismuth H: Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med. 128:810–816. 1998. View Article : Google Scholar : PubMed/NCBI
13	Chan HL and Jia J: Chronic hepatitis B in Asia-new insights from the past decade. J Gastroenterol Hepatol. 26 Suppl 1:131–137. 2011. View Article : Google Scholar : PubMed/NCBI
14	Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR and Rehermann B: Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis. 205:763–771. 2012. View Article : Google Scholar : PubMed/NCBI
15	Ellinger I, Rothe A, Grill M and Fuchs R: Apical to basolateral transcytosis and apical recycling of immunoglobulin G in trophoblast-derived BeWo cells: Effects of low temperature, nocodazole, and cytochalasin D. Exp Cell Res. 269:322–331. 2001. View Article : Google Scholar : PubMed/NCBI
16	Ellinger I, Schwab M, Stefanescu A, Hunziker W and Fuchs R: IgG transport across trophoblast-derived BeWo cells: A model system to study IgG transport in the placenta. Eur J Immunol. 29:733–744. 1999. View Article : Google Scholar : PubMed/NCBI
17	Zheng Y, Huang Z, Chen X, Tian Y, Tang J, Zhang Y, Zhang X, Zhou J, Mao Q, Ni B, et al: Effects of telbivudine treatment on the circulating CD4⁺ T-cell subpopulations in chronic hepatitis B patients. Mediators Inflamm. 2012:7898592012. View Article : Google Scholar : PubMed/NCBI
18	von Boehmer H: Mechanisms of suppression by suppressor T cells. Nat Immunol. 6:338–344. 2005. View Article : Google Scholar : PubMed/NCBI
19	Jones SW, Roberts RA, Robbins GR, Perry JL, Kai MP, Chen K, Bo T, Napier ME, Ting JP, Desimone JM, et al: Nanoparticle clearance is governed by Th1/Th2 immunity and strain background. J Clin Invest. 123:3061–3073. 2013. View Article : Google Scholar : PubMed/NCBI
20	Wang K, Fan X, Fan Y, Wang B, Han L and Hou Y: Study on the function of circulating plasmacytoid dendritic cells in the immunoactive phase of patients with chronic genotype B and C HBV infection. J Viral Hepat. 14:276–282. 2007. View Article : Google Scholar : PubMed/NCBI